Q2 EPS Estimates for iTeos Therapeutics Reduced by Wedbush

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities researchers at Wedbush lowered their Q2 2025 EPS estimates for shares of iTeos Therapeutics in a report issued on Monday, July 21st. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.56) per share for the quarter, down from their prior estimate of ($1.48). Wedbush has a “Outperform” rating and a $10.50 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($2.07) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($4.60) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.26) EPS.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14.

A number of other analysts also recently issued reports on ITOS. HC Wainwright downgraded shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, May 14th. Piper Sandler downgraded shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Wells Fargo & Company reissued an “equal weight” rating and set a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Finally, Leerink Partnrs downgraded shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.64.

iTeos Therapeutics Price Performance

NASDAQ:ITOS opened at $10.13 on Thursday. The firm has a market capitalization of $387.68 million, a P/E ratio of -3.33 and a beta of 1.49. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.13. The company’s fifty day moving average price is $9.79 and its 200-day moving average price is $7.97.

Institutional Investors Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ITOS. Strs Ohio acquired a new stake in shares of iTeos Therapeutics during the first quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $42,000. CWM LLC boosted its stake in shares of iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock valued at $51,000 after purchasing an additional 6,936 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of iTeos Therapeutics in the first quarter valued at approximately $65,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at iTeos Therapeutics

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the transaction, the insider directly owned 2,108,594 shares of the company’s stock, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the transaction, the insider directly owned 3,452,797 shares in the company, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,939,307 shares of company stock valued at $16,202,116. 12.50% of the stock is currently owned by company insiders.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.